Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Status:
Terminated
Trial end date:
2016-01-08
Target enrollment:
Participant gender:
Summary
Assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the
use of inhaled corticosteroid (ICS) in pediatric and adult participants with severe
Immunoglobulin E (IgE)-mediated asthma inadequately controlled with high doses of
corticosteroids.